CONCLUDE: Ablation of Consecutive Atrial Tachycardia

Sponsor
Evangelical Hospital Düsseldorf (Other)
Overall Status
Recruiting
CT.gov ID
NCT05239364
Collaborator
(none)
100
2
2
47.3
50
1.1

Study Details

Study Description

Brief Summary

Ablation of consecutive atrial tachycardia (AT) after ablation of atrial fibrillation (AF) or cardiac surgery can be challenging due to complex substrate and AT mechanisms. A substantial portion of patients is known to show various tachycardias and recurrences occur in a noticeable number of cases. With the availability of novel ultra-high-density mapping techniques characterization and understanding of AT mechanisms and underlying substrate can be improved. Aim of this prospective, multi-center, randomized study is to compare a standard AT ablation approach versus minimalized ablation of the clinical AT in regards to arrhythmia free survival.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Catheter ablation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Ablation of CONseCutive atriaL Tachycardia gUided by Ultra-high-DEnsity Mapping
Actual Study Start Date :
Dec 22, 2020
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Standard approach

Patients will receive a standard approach for ablation of atrial tachycardia.

Procedure: Catheter ablation
Catheter-based ablation of arrhythmias using radiofrequency.

Experimental: Minimalized approach

Patients will receive a minimalized approach for ablation of atrial tachycardia.

Procedure: Catheter ablation
Catheter-based ablation of arrhythmias using radiofrequency.

Outcome Measures

Primary Outcome Measures

  1. Recurrence of any sustained arrhythmia (>30 sec.) [1 year]

Secondary Outcome Measures

  1. Inducibility of atrial tachycardia (AT) after ablation of clinical/primary AT (partial success) [Intraprocedural]

    Categorical variable (yes/no)

  2. Predictability of secondary AT by analysis of clinical AT map and voltage map [Intraprocedural]

  3. Procedure duration time [Intraprocedural]

  4. Fluoroscopy time [intraprocedural]

  5. Total radiofrequency application time [intraprocedural]

  6. Ablated area (cm2) [intraprocedural]

  7. Number of blocked lines [intraprocedural]

  8. Area of low voltage in sinus map (cm2) [Intraprocedural]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Consecutive AT subsequent to prior AF ablation procedure or cardiac surgery

  • Surface ECG-documentation of AT as primary clinical arrhythmia

  • ECG indicating stable, map-able AT (stable activation sequence, and CL stability) with cycle length ≥ 200ms

Exclusion Criteria:
  • < 18 years

  • No previous atrial fibrillation ablation procedure or cardiac surgery

  • Pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment

  • History of hemorrhagic diathesis or other coagulopathies

  • Contraindications for oral anticoagulation

  • Hyper- or hypothyroidism

  • Has any condition that would make participation not be in the best interest of the subject

Contacts and Locations

Locations

Site City State Country Postal Code
1 Evangelic Hospital Düsseldorf Düsseldorf North Rhine-Westfalia Germany 40217
2 Universitätsklinikum Schleswig Holstein Kiel Schleswig Holstein Germany 24105

Sponsors and Collaborators

  • Evangelical Hospital Düsseldorf

Investigators

  • Principal Investigator: Christian Meyer, MD, Evangelic Hospital Düsseldorf

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Christian Meyer, Prof. Dr. Christian Meyer, Evangelical Hospital Düsseldorf
ClinicalTrials.gov Identifier:
NCT05239364
Other Study ID Numbers:
  • CONCLUDE
First Posted:
Feb 14, 2022
Last Update Posted:
Apr 14, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Christian Meyer, Prof. Dr. Christian Meyer, Evangelical Hospital Düsseldorf
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 14, 2022